Rabbit Models for Alzheimer's Disease

submitted by: alex01

Diana Woodruff-Pak (Temple University, Philadelphia, PA) used cholesterol-fed rabbits as a model of AD for evaluation of currently available and potential anti-Alzheimer drugs. These animals developed typical Alzheimer pathology, including behavioral changes and deposition of ß-amyloid and even
tau. Galantamine and donepezil partially protected animals from Alzheimer symptomatology.

Sodium Channels and Pain

submitted by: alex01

S. Waxman, MD, PhD. - Medical need for new analgesics is discussed by S. Waxman (Yale University) who evaluated the role of selective subtypes of sodium channels, particularly 1.7 and 1.8 subtypes, in the perception of pain. There is an unmet medical need for drugs to treat chronic pain and inhibitors of
selective sodium channels are in development as novel analgesics.

AMPA Ligands in Neuroprotection

submitted by: alex01
Michael Spedding (Institute Internatinales Servier, Paris, France) described how neuroprotection can be achieved by either by blockade or by stimulation of AMPA (a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptors. Low threshold AMPA receptor stimulation leads to the release of BDNF (brain-derived neurotrophic factor) which is neuroprotective. Blockade of AMPA receptors reduces excitotoxicity leading to neuroprotection. BDNF is a major activity-dependent neurotrophic factor...

TGFß & Alzheimer's Disease

submitted by: alex01

R.A. Flavell (Yale University, New Haven, CT) discusses the role of Transforming Growth Factor ß (TGFß) in disease. In the central nervous system of a murine model of AD this cytokine appears to prevent macrophages from attacking ß-amyloid. Flavell visualizes that selective blockade of this TGFß
activity could lead to the destruction of plaques in patients with AD.

Antibiotics: Is a Strong Offense the Best Defense? (Part 2 of 3) MWV

submitted by: MicrobeWorld
On September 18, 2008 at the Koshland Science Museum in Washington, D.C., Dr. Stuart Levy, professor of Molecular Biology and Microbiology at Tufts University School of Medicine and Dr. Linda Tollefson, Assistant Commissioner for Science at the U.S. Food and Drug Administration, discussed how to optimize antibiotic use and how to minimize the emergence of drug resistant pathogens. In part 2 of this 3 part video series, Dr. Levy discusses how antibiotic resistance develops, the development...

Drug Discovery: African Sleeping Sickness

linked profile(s): Rommie
submitted by: apryl

Rommie Amaro, Computational and Theoretical Biophysical Chemist, discusses how she uses the resources at SDSC to conduct her drug discovery research on African Sleeping Sickness. Originally posted by SDSC on SDSC's CI Channel at: www.cichannel.org